肿瘤外泌体PD-L1可与细胞毒性CD8 T细胞表面的PD-1结合，抑制CD8 T细胞的增殖及活化，是肿瘤外泌体抑制宿主免疫的重要机制。然而肿瘤外泌体与CD8 T细胞相互作用的分子机制并不清楚。2022年1月25日，宾夕法尼亚大学郭巍课题组Developmental Cell在线发表了题为ICAM-1-mediated adhesion is a prerequisite for exosome...
ETIDS),利用该系统,研究团队进一步证实肿瘤细胞外泌体是以配体-受体介导的模式与CD8+ T细胞发生相互作用,并肯定了ICAM-1和LFA-1的结合对于PD-L1和PD-1相互作用的重要性。总体
PD-1是减缓t细胞生长的检查点。PD-1(红色)从t细胞表面延伸,与抗原提呈细胞的配体蛋白PD-L1(黄色)相互作用。 免疫反应的激活:抗原提呈细胞激活t淋巴细胞(较小的细胞)。放大:与MHC II类分子和抗原复合物的t细胞受体。 通过抗原提呈细胞和t细胞的相互作用参与免疫系统激活和抑制的膜蛋白。MHC-II与t细胞受体以及CD4和...
PD1CARDear Editor,Chimeric antigen receptor modifed T(CAR-T)cell therapy has shown potent antitumor activity against relapsed and refractory hematological malignancies.However,its efficacy in solid tumors is limited,partly because of the inhibition of PD-L1/PD-1 signaling on CAR-T cells in solid ...
筛查包括41种宿主细胞因子和趋化因子,包括MSD人类V-plex筛查面板1生物标记物集中的39种分析物,以及可溶性PD-1(sPD-1)和可溶性PD-L1(sPD-L1)。每个血清生物标记物的水平与其相应的肝脏基因表达相关。然后,确定与肝内表达水平密切相关的生物标记物是否可以识别免疫高和免疫低人群。该分析包括两种趋化因子:ICAM-1和...
糖皮质激素对肿瘤细胞PD-L1表达的调控作用及机制研究 热度: 细胞外基质刚度对肿瘤细胞自我更新的调控作用及机制研究 热度: 中国科学技术大学 硕士学位论文 肿瘤细胞中E2F1对ICAM-1的调控作用及机制的初步探索 姓名:***申请学位级别:硕士 专业:细胞生物学 指导...
A. et al. The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep. 22, 2978–2994 (2018). Article CAS PubMed Google Scholar Kim, S. J., Asfaha, S. & Dick, F. A. CDK4 inhibitors thwart ...
(14-5982)CD274 (PD-L1, B7-H1) Monoclonal Antibody (MIH5), eBioscience an Antibody byInvitrogen Antibodies Applications: Neutralization (16-0111)CD11a (LFA-1alpha) Monoclonal Antibody (M17/4), Functional Grade, eBioscience an Antibody byInvitrogen Antibodies ...
rTNFα did not affect the expression of inhibitory ligands (transforming growth factor-β (TGF-β) and programmed cell death-ligand 1 (PD-L1); supplemental Figure 5A) or DNAX accessory molecule 1 (DNAM-1) ligands (CD112 and CD155; supplemental Figure 5B) on AML, which were previously ...
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65. Article CAS PubMed PubMed Central Google Scholar Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, ...